– Earnings per share of $0.80 expected for Immunic, Inc. (NASDAQ:IMUX) this quarter
Wall Street analysts expect Immunic, Inc. (NASDAQ:IMUX – Get Rating) to report earnings of ($0.80) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Immunic’s earnings, with the lowest EPS estimate being $0.90 and the highest estimate being $0.70. Immunic posted earnings per share of ($1.63) in the same quarter last year, which would indicate a positive growth rate of 50.9% year over year. The company is due to release its next quarterly earnings report on Thursday, May 5.
According to Zacks, analysts expect Immunic to report annual earnings of $3.28 per share for the current fiscal year, with EPS estimates ranging from $3.81 to $2.47. For the next fiscal year, analysts expect the company to post earnings of ($3.57) per share, with EPS estimates ranging from ($5.04) to ($2.78). Zacks EPS averages are an average average based on a survey of sell-side research companies that cover Immunic.
Immunic (NASDAQ:IMUX – Get Rating) last announced its results on Thursday, February 24. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.01. In the same quarter of the previous year, the company had earned earnings per share of ($0.46).
Small cap stocks – and penny stocks in particular – tend to march to the beat of their own beater.
Low-priced, “penny” stocks like these offer a great way to make money regardless of the direction of the markets as a whole…
Click here to see how you can get the names and stock symbols of the four penny stocks.
IMUX has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a price target of $25.00 on Immunic shares in a Monday, Dec. 20 research note. Zacks Investment Research downgraded Immunic’s shares from a “buy” rating to a “hold” rating in a Monday, Feb. 21 research note. Finally, Wedbush reiterated a “buy” rating and set a price target of $61.00 on Immunic shares in a Saturday, February 26 research report. One equity research analyst gave the stock a hold rating and four gave the stock a buy rating. Based on MarketBeat data, Immunic currently has an average rating of “Buy” and an average target price of $42.00.
Several large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its stake in Immunic shares by 9.4% in the fourth quarter. JPMorgan Chase & Co. now owns 11,262 shares of the company worth $108,000 after buying 965 additional shares last quarter. Royal Bank of Canada increased its holdings of Immunic shares by 10.3% in the third quarter. Royal Bank of Canada now owns 13,350 shares of the company worth $118,000 after acquiring 1,242 more shares in the last quarter. Citigroup Inc. increased its equity stake in Immunic by 38.8% in the fourth quarter. Citigroup Inc. now owns 5,525 shares of the company worth $53,000 after acquiring 1,544 additional shares in the last quarter. American International Group Inc. increased its stake in Immunic shares by 17.9% in the third quarter. American International Group Inc. now owns 10,245 shares of the company worth $91,000 after acquiring 1,554 additional shares in the last quarter. Finally, Deutsche Bank AG increased its stake in Immunic shares by 16.9% in the third quarter. Deutsche Bank AG now owns 10,768 shares in the company worth $95,000 after acquiring 1,559 additional shares in the last quarter. Hedge funds and other institutional investors hold 49.15% of the company’s shares.
Shares of NASDAQ:IMUX traded at $0.39 in Friday’s midday session, hitting $10.49. 3,833 shares of the stock have been traded, compared to its average volume of 340,545. The stock has a market capitalization of $292.74 million, a PE ratio of -2.61 and a beta of 1, 84. The company’s 50-day moving average is $11.65 and its two-hundred-day moving average is $10.04. Immunic has a one-year minimum of $6.96 and a one-year maximum of $18.00.
About Immunic (Get an assessment)
Immunic, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. He focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis and psoriasis. The company’s products include IMU-838, IMU-935 and IMU-856.
Further reading
Get a Free Copy of Zacks Research Report on Immunic (IMUX)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]marketbeat.com.
Should you invest $1,000 in Immunic right now?
Before you consider Immunic, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Immunic wasn’t on the list.
Although Immunic currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here